PHILADELPHIA, Jan. 4, 2011 /PRNewswire/ -- ERT (Nasdaq: ERES), announced today that Dr. Joel Morganroth, the Company's Chairman and CEO, and Keith Schneck, the Company's Chief Financial Officer, are scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference at 9:30 AM PST on January 13, 2011 in San Francisco, California.
Interested parties may access the presentation by visiting the Company's corporate website at http://www.ert.com. The webcast may also be accessed at http://jpmorgan.metameetings.com/webcasts/healthcare11/directlink?ticker=ERES. The webcast will be available via replay for 90 days.
Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. It is also a leading provider of centralized respiratory technology and services to evaluate pulmonary function efficacy and safety in clinical development. Sponsors can further use the Company's solutions to streamline the clinical trials process by automating the collection, analysis, and distribution of ePRO clinical data using multi-mode technology in all phases of clinical development as well as selected medical devices for the clinical trials and healthcare industries.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Copyright©2010 PR Newswire.
All rights reserved